ArticleImmunologic research2025
Immunomodulatory activities of carbon quantum dots on the primary macrophages and whole splenocytes.
Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantum dots, because of some of their fascinating features, like continuous radiation emission, crossing the biological barrier, and potential for drug carrying, have emerged as versatile nanomaterials in enormous applications relating to drug development and health sciences. Among such quantum dots, carbon quantum dots have gained widespread attention due to their low toxicity, high biocompatibility, and excellent photostability. The present work investigates the immunomodulatory properties of CQDs with diverse chemical characteristics against primary macrophages and whole splenocytes. Since macrophages are important regulators of immune responses, their isolation and activation by toll-like receptor agonists were performed to evaluate the production of pro-inflammatory cytokines and intracellular signaling pathways. Our data indicate that different CQD formulations possess specific immunomodulatory activities, while some of them reveal adjuvant capabilities; others act anti-inflammatory. Importantly, the zinc-containing CQDs enhance pro-inflammatory responses, which may find applications as vaccine adjuvants. These findings highlight the therapeutic possibilities of CQDs in the treatment of inflammatory diseases and enhancement of vaccine efficacy.
Indexed as
Identifiers
40580345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.